Vanguard Global Advisers
PCRX icon

Vanguard Global Advisers’s Pacira BioSciences PCRX Stock Holding History

Vanguard Global Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Sell
82,712
-1,560
-2% -$36.9K ﹤0.01% 1233
2026
Q1 		$1.9M Buy
+84,272
New +$1.87M ﹤0.01% 1228

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's PCRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Pacira BioSciences (PCRX) stake by 1.9% in Q2 2026, selling an estimated $36.9K and leaving 82,712 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Vanguard Global Advisers first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 250 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Vanguard Global Advisers held 82,712 shares of Pacira BioSciences worth $2.1M as of Q2 2026.
  • Vanguard Global Advisers sold 1,560 Pacira BioSciences shares in Q2 2026, an estimated $36.9K.
  • Pacira BioSciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1233 holding.
  • Vanguard Global Advisers first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 250 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.